Join

Compare · FLAG vs MRNA

FLAG vs MRNA

Side-by-side comparison of First Light Acquisition Group Inc. (FLAG) and Moderna Inc. (MRNA): market cap, price performance, sector, and recent activity on the wire.

Summary

  • Both FLAG and MRNA operate in Biotechnology: Biological Products (No Diagnostic Substances) (Health Care), so they compete in similar markets.
  • MRNA is the larger of the two at $64.66B, about 228.8x FLAG ($282.6M).
  • Over the past year, FLAG is up 0.0% and MRNA is up 84.6% - MRNA leads by 84.6 points.
  • MRNA has hit the wire 8 times in the past 4 weeks while FLAG has been quiet.
  • MRNA has more recent analyst coverage (25 ratings vs 0 for FLAG).
PerformanceFLAG+0.00%MRNA+8.24%
2026-01-29+0.00%2026-04-24
MetricFLAGMRNA
Company
First Light Acquisition Group Inc.
Moderna Inc.
Price
$27.42+268.55%
$50.74-3.98%
Market cap
$282.6M
$64.66B
1M return
+0.00%
-5.22%
1Y return
+0.00%
+84.64%
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
Biotechnology: Biological Products (No Diagnostic Substances)
Exchange
NYSE
NASDAQ
IPO
2021
2018
News (4w)
0
8
Recent ratings
0
25
FLAG

First Light Acquisition Group Inc.

First Light Acquisition Group, Inc. does not have significant operations. It intends to effect a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses or entities. The company was incorporated in 2021 and is headquartered in Reston, Virginia.

MRNA

Moderna Inc.

Moderna, Inc., a biotechnology company, develops therapeutics and vaccines based on messenger RNA for the treatment of infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and auto-immune diseases. As of March 9, 2021, the company had 13 programs in clinical trials and a total of 24 development programs in six modalities comprising prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted and cell surface therapeutics, and systemic intracellular therapeutics. The company has strategic alliances with AstraZeneca PLC, Merck & Co., Inc., Vertex Pharmaceuticals Incorporated, Vertex Pharmaceuticals (Europe) Limited, the Biomedical Advanced Research and Development Authority, the Defense Advanced Research Projects Agency, the National Institute of Allergy and Infectious Diseases, the National Institutes of Health, the Coalition for Epidemic Preparedness Innovations, and Bill & Melinda Gates Foundation. Moderna, Inc. also has collaborations with Lonza Ltd. for the manufacture of COVID-19 vaccine; and Catalent Inc., Laboratorios Farmacéuticos Rovi, S.A., Recipharm, and Lonza Group for fill-finish manufacturing of its COVID-19 vaccine candidate, as well as Aldevron, LLC for supporting COVID-19 vaccine and additional programs in company's clinical development pipeline. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.

Latest FLAG

Latest MRNA